VIENNA — The need for renal replacement therapy has stabilized in many parts of the Western world, new registry data show. "There was a continuous increase in the incidence of renal replacement therapy from the 1980s until the early 2000s, and ... General Medicine eJournal, 1 day ago
Global Continuous Renal Replacement Therapy (CRRT) Market 2016 - Industry Forecast to 2025 for the $1.6 Billion Market - 4 Traders, 2 days ago
FMI Releases New Report on the Continuous Renal Replacement Therapy Market 2016-2026 - MyNewsDesk, 1 week ago
Share this content: Early initiation of renal replacement therapy (RRT) significantly improves 90-day survival among critically ill patients with acute kidney injury (AKI), researchers reported at the European Renal Association-European Dialysis ...Renal & Urology News, 6 days ago Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit New England Journal of Medicine, 2 weeks ago Risk Factors ID'd for Early Mortality After Starting CRRT Renal & Urology News, 2 days ago Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients New England Journal of Medicine, 2 days ago
Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!
K.Doenyas-Barak , I.Beberashvili and S.Efrati The role of RRT in the treatment of lactic acidosis in general, and in metformin-associated lactic acidosis (MALA) in particular, has been the subject of several trials. Due to the low molecular ...Critical Care, 3 weeks ago
Neutrophil gelatinase-associated lipocalin elimination by renal replacement therapy: minding the membrane!
Letter Open Access Critical Care 2016 20 :87 DOI: 10.1186/s13054-016-1258-9 Honore and spapen.2016 Published: 5April2016 The Letter to this article has been published in Critical Care 2016 20 :20 This comment refers to ...Critical Care, 1 month ago
Baxter's 1Q16 Earnings Beat Estimates, Post Improved Margins ( Continued from Prior Part ) 1Q16 performance Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$898 million, or ~38%, came from Baxter's Renal ...Yahoo! Finance UK and Ireland, 2 weeks ago
More from: , Yahoo! Finance...and 1 other sources
SEATTLE--( BUSINESS WIRE )--Omeros Corporation(NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company's lead ...Business Wire, 1 month ago Omeros Corporation Release: Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases BioSpace, 1 month ago OMEROS : Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases 4 Traders, 1 month ago
Monitoring of Potential Safety Events and Vital Signs during Active Mobilization of Patients Undergoing Continuous Renal Replacement Therapy in a Medical Intensive Care Unit
Background/Aims: This study aims to evaluate potential safety events and vital sign changes during active mobilization physical therapy (PT) in critically ill patients undergoing continuous renal replacement therapy (CRRT). Methods: A retrospective ...Blood Purification, 1 week ago
Biotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its Promise.
Biotech continues to build on the strength it demonstrated last week and biotech indices surged over two percent on Tuesday after a solid start to the week on Monday. Monday's rise was mainly led by the small cap names in the sector, probably helped ...Seeking Alpha, 4 days ago
Aytu BioScience Enters $2 Billion Testosterone Replacement Market With Acquisition Of U.S. Commercial Rights To Natesto ENGLEWOOD, Colo. , April 25, 2016 /PRNewswire/ —Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company ...Pharma Live, 1 month ago Aytu BioScience, Inc. (AYTU: OTCQX U.S. Premier) | Aytu BioScience Enters $2 Billion Testosterone Replacement Market with Acquisition of U.S. Commercial Rights to Natesto® OTC Markets, 1 month ago Aytu BioScience Enters $2 Billion Testosterone Replacement Market with Acquisition of U.S. Commercial Rights to Natesto® Bloomberg, 1 month ago Aytu BioScience Enters 2 Billion Testosterone Replacement Market with Acquisition of US Commercial Rights to Natesto Pharma Focus Asia, 1 month ago
Bristol-Myers Squibb's Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
PRINCETON, N.J.--(Business Wire)-- Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of recurrent or ...Digital Journal, 1 month ago Bristol-Myers Squibb's Opdivo(R) (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck TradingCharts.com, 1 month ago Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) Yahoo! Singapore, 1 month ago MERCK : Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) 4 Traders, 1 month ago
on your WebpageAdd Widget >Get your members hooked!